Zogenix, Inc. (NASDAQ: ZGNX) Investor Securities Class Action Lawsuit 04/12/2019

If you purchased a significant amount of shares of Zogenix, Inc. (NASDAQ: ZGNX) between February 6, 2019 and April 8, 2019, and / or if you purchased any NASDAQ: ZGNX shares prior to February 2019 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: June 11, 2019. NASDAQ: ZGNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Zogenix
Case Name: 
Zogenix Shareholder Class Action Lawsuit 04/12/2019
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: ZGNX
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
04/12/2019
Class Period Begin: 
02/06/2019
Class Period End: 
04/08/2019
Court of Filing: 
U.S. District Court for the Northern District of California
Deadline To File for Lead: 
06/11/2019
Summary: 

An investor in shares of Zogenix, Inc. (NASDAQ: ZGNX) filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by Zogenix, Inc. in connection with certain allegedly false and misleading statements made between February 6, 2019 and April 8, 2019.

Emeryville, CA based Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is ZX008, which is also known commercially by its trademarked name “FINTEPLA.” FINTEPLA is a low-dose fenfluramine that is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. On February 6, 2019, Zogenix announced the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for FINTEPLA.
On April 8, 2019, Zogenix, Inc. announced it received a refusal to file letter from the U.S. Food and Drug Administration (“FDA”) regarding Zogenix’s new drug application (“NDA”) for FINTEPLA, Zogenix’s proposed treatment for seizures associated with Dravet syndrome. Zogenix, Inc. told investors that “the FDA determined that the NDA... was not sufficiently complete to permit a substantive review... [F]irst, certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine; and, second, the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA.”

According to the complaint the plaintiff alleges on behalf of purchasers of Zogenix, Inc. (NASDAQ: ZGNX) common shares between February 6, 2019 and April 8, 2019, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 6, 2019 and April 8, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that Zogenix’s NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset, that consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.